In just over a week, the global cardiovascular community will descend upon the Palais des Congrès de Paris for EuroPCR 2026. As the premier educational course in interventional medicine, EuroPCR stands as the definitive forum for the exchange of cutting-edge science, procedural innovation, and clinical best practices. This year, the event returns to the French capital—a city currently in full spring bloom—to host a staggering 166 late-breaking clinical trials and nearly 2,000 clinical cases, solidifying its reputation as the heartbeat of the interventional cardiology calendar.
The theme for this year’s gathering, "Education Saves Lives: Preventing and Solving Complications," underscores a shift toward the mastery of procedural nuance and long-term patient safety. With over 800 hours of programming and 3,000 faculty members, the meeting serves as a massive knowledge-transfer engine designed to sharpen the clinical acumen of the thousands of interventionalists expected to attend.
The Core Mission: Advancing Interventional Standards
The scientific direction of EuroPCR 2026 is steered by course directors Dr. Thomas Cuisset (CHU La Timone, Marseille), Dr. Nicolas Dumonteil (Clinique Pasteur, Toulouse), and Dr. Nieves Gonzalo (San Carlos University Hospital, Madrid). Their vision for the 2026 curriculum emphasizes not just the introduction of new hardware, but the rigorous evaluation of long-term outcomes and the standardization of complex procedural techniques.
The event’s structure is meticulously designed to accommodate every tier of the medical community. The pre-course period, commencing on Monday, May 18, is dedicated to the next generation of specialists through the PCR Fellows Course, while the highly anticipated Innovators Day facilitates dialogue between engineers, clinicians, and regulatory stakeholders. Simultaneously, a dedicated day of programming focused on coronary physiology promises to refine the decision-making processes that underpin modern interventional care.
A Chronological Overview of Scientific Breakthroughs
The scientific heartbeat of EuroPCR 2026 is concentrated in 18 "hotline" and late-breaking clinical trial sessions. These sessions are distributed across the four-day meeting to ensure a constant flow of new data.
Tuesday, May 19: The Opening Salvo
The first hotline session at noon will tackle the persistent challenge of calcified lesions, an area where technological advancements have accelerated rapidly. This will be followed by a noon session exploring the next generation of coronary devices, including ultra-thin-strut bioresorbable scaffolds, biodegradable polymer DES, and the "unlocking" coronary device technology known as the Bioadaptor. Afternoon sessions will pivot toward tricuspid valve intervention outcomes and the optimization of pharmacological management for coronary artery disease (CAD).
Wednesday, May 20: The "Major" Studies
Wednesday marks the summit of the conference. At 9:45 AM in the Theatre Bleu, the course directors will unveil three pivotal trials that are expected to influence clinical guidelines globally:
- CAD and TAVI: A comprehensive patient-level meta-analysis exploring the clinical merits of revascularization in patients presenting with both coronary artery disease and aortic stenosis.
- Left Main CAD Long-term Follow-up: A deep dive into the comparative outcomes of CABG versus PCI for left main disease. This study arrives at a critical juncture, as the medical community continues to navigate the complex legacy of the EXCEL and NOBLE trials.
- LAAO vs. DOACs: An age-stratified comparative analysis of left atrial appendage occlusion (LAAO) against direct oral anticoagulants (DOACs) in atrial fibrillation patients. This follows recent, sometimes contradictory, evidence from trials like CHAMPION-AF and CLOSURE-AF, and promises to provide clarity on the appropriate patient selection for structural heart intervention.
Wednesday also features afternoon deep dives into innovative ACS strategies, including the use of drug-coated balloons and intravascular lithotripsy, as well as critical data on TAVI (including 3-year SMART trial outcomes and 2-year LANDMARK data).
Thursday, May 21: Refined Strategies
Thursday’s agenda is heavily weighted toward structural and complex coronary interventions. Two morning sessions will focus on TAVI procedural strategies, followed by an 11:00 AM hotline on coronary revascularization, which will include randomized data on LV unloading in complex PCI and the PROTECT-EU registry results. The afternoon shifts toward the role of intracoronary imaging and microvascular physiology.
Friday, May 22: Closing Perspectives
The final day concludes with a focus on pulmonary embolism and the ongoing evolution of LAAO, including a meta-analysis comparing mechanical thrombectomy with catheter-directed thrombolysis.
Supporting Data: The Magnitude of the Program
The sheer scale of EuroPCR 2026 is best understood through its numbers. With 1,984 clinical cases and 1,129 abstracts, the program offers a panoramic view of the current state of interventional medicine. The integration of 500+ sessions ensures that attendees are not merely passive listeners but active participants in the evolution of their field.
The "Live Cases" component remains a cornerstone of the event, broadcasting from eight world-class centers, including the Cleveland Clinic in London, the Leipzig Heart Centre, and the University Hospital Basel. These 17 live sessions—ranging from mitral valve-in-valve procedures to complex CTO (chronic total occlusion) revascularization—provide an unparalleled look at the "how-to" of modern interventional cardiology.
Implications for Clinical Practice
The implications of the data presented at EuroPCR 2026 are profound. By addressing the "mortality controversy" in left main disease and the "noninferiority" debates surrounding LAAO, these trials are set to reshape clinical decision-making.
Furthermore, the new dedicated tracks for CTOs and the expanded skills labs for calcification demonstrate a commitment to procedural excellence. The Innovation Hub, a collaborative effort with TCT, will highlight the integration of artificial intelligence into academic and clinical cardiology, signaling a paradigm shift toward data-driven, automated procedural support.
Professional Perspectives and Community Engagement
As with previous years, the team at TCTMD—myself, Yael L. Maxwell, and L.A. McKeown—will be on the ground to capture the nuance of these developments. We invite colleagues to reach out with stories that highlight the real-world impact of these technologies.
Beyond the scientific rigor, EuroPCR continues to be a social nexus. Whether through the simulation-based learning labs or the informal corridors of the Palais des Congrès, the conference fosters the human connections necessary for the global medical community to thrive. I look forward to the scientific insights and, perhaps, the opportunity to find a running partner for the Parisian streets during the early morning hours before the day’s sessions begin.
Conclusion
EuroPCR 2026 is positioned to be a transformative event. By balancing the "hot" science of late-breaking trials with the practical, hands-on education of simulation labs and live cases, the organizers have crafted an environment where theoretical research meets clinical reality. For the interventionalist, this week in Paris is more than just a conference; it is a vital checkpoint in the ongoing effort to prevent, treat, and resolve the most complex challenges in cardiovascular medicine.
For those unable to attend in person, the full program and digital resources remain available through the official PCR portal, ensuring that the lessons of Paris reach every corner of the globe. As we look toward the future of the field, the consensus remains clear: education, grounded in rigorous evidence and shared experience, remains our most potent tool in the fight to save lives.
